As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific...
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver...
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with DepressionMALVERN, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE)...
BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA...
Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September...
Company continues pioneering research on BCI-enabled system to restore mobility after spinal cord injuryEINDHOVEN, The Netherlands, Sept. 19, 2024 (GLOBE...
New messaging reflects TFS's commitment to patient-centered clinical research and global partnerships LUND, Sweden, Sept. 19, 2024 /PRNewswire/ -- TFS HealthScience...
This seven-month online program is designed to help senior medtech executives step up to a C-suite role and create value...
CARLSBAD, Calif., Sept. 18, 2024 /PRNewswire/ -- The pioneering health and wellness brand formerly known as Neurohacker Collective, has recently completed...
Investment to bolster leading multi-site clinical trial organization to further scale across therapeutic areas and geographies APEX, N.C. and SAN...
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50...
The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers...
Detailing the intricate process of early embryogenesis, this year's winning video provides insights into fundamental biological processes with far-reaching implications....
ORLANDO, Fla., Sept. 16, 2024 /PRNewswire/ -- Anervea.ai, a global leader in AI-powered commercialization solutions for the Pharmaceutical, Life Sciences,...
SAN FRANCISCO, Sept. 16, 2024 /PRNewswire/ -- Darmiyan, Inc., a pioneer in brain technology, is proud to announce the launch...
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints...
RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is cementing its...
Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and...